Generation Bio Co. (GBIO) Total Business Assets

Brandmark of Generation Bio Co. (GBIO)

Generation Bio Co. (GBIO) is a pioneer in creating cell-free gene delivery systems, granting the company significant pricing power. The company is aggressively protecting its intellectual property to avoid a direct price war. The market trend for total assets, which currently stands at 185.35, confirms the scale of the business. The brand has earned recognition for its precision platform for treating rare genetic pathologies.

Generation Bio (GBIO) Company Total Assets: for the period 07/04/2022 - 02/21/2026

Analytical breakdowns for generationbio.com (GBIO)

- price and consensus price forecast:
Market Price Generation Bio|GBIO - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization GBIO|GBIO - Total Company Value
- book capitalization data:
Equity per Share Generation Bio|GBIO - Book Capitalization|Market Capitalization to Book Value Ratio generationbio.com|GBIO - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio Generation Bio Co.|GBIO - Long-Term Debt to Capital|Current Liabilities to Capital Generation Bio|GBIO - Company Debts|Debt to Book Value Ratio GBIO
Comprehensive company analysis:Generation Bio Co.
Manufactured product of Generation Bio Co.

The trend in consolidated asset levels reflects the scale of resources Generation Bio (GBIO) requires for expansion into the non-viral gene therapy market via ceDNA platforms. This metric, reverse-calculated through ROA, combines liabilities and equity, allowing investors to eliminate accounting anomalies through the analysis of daily fluctuations and assess the efficiency of asset management amid high demand for technology licensing.

Competing companies

Tempus AI, Inc (TEM) - Company Assets|Company Total Assets Qiagen (QGEN)|Total Business Assets IONS|Aggregate Company Assets Repligen Corp. RGEN|Total Business Assets Avidity Corp (RNA)|Company Total Assets CRSP (CRISPR Therapeutics AG)|Company Total Assets genedx.com WGS|Company Total Assets RARE|BEAM - Company Balance Sheet Assets|Company Total Assets SRPT|TWST (Twist Bioscience Corp) - Company Assets|Aggregate Company Assets 10x Genomics, Inc. (TXG)|Total Business Assets intelliatx.com|Stoke Therapeutics, Inc. - Company Total Assets|Company Assets BLFS (BioLife Solutions Inc)|Aggregate Company Assets Wave Life Sciences Corp|Aggregate Asset Value Maze Therapeutics Corp MAZE|Sionna Therapeutics Inc - Company Total Assets|primemedicine.com (PRME) - Company Total Assets|TSHA - Cumulative Company Assets|uniQure NV (QURE) - Aggregate Business Assets|MGTX: Company Total Assets|Company Total Asset Base RGNX|Solid Biosciences Inc. - Aggregate Company Assets|Company Assets OCGN (ocugen.com)|PACB - Aggregate Company Assets|BNTC - Total Business Assets|Cumulative Company Assets Design Pharma (DSGN)|RCKT - Aggregate Asset Value|4D Molecular Therapeutics (FDMT) - Company Total Assets|Lexeo Therapeutics, Inc. (LXEO) - Aggregate Company Assets|KRRO: Company Total Assets|Company Total Asset Base EDIT|Silence Therapeutics Inc. - Aggregate Company Assets|Company Assets proqr.com PRQR|Cumulative Company Assets Codexis|Aggregate Asset Value sangamo.com SGMO|NAUT: Company Total Assets|MGX: Cumulative Company Assets|Aggregate Company Assets DTIL|Company Assets Boundless Bio Inc|XCUR: Cumulative Company Assets|Company Total Asset Base Celsion Corporation|PHIO: Company Total Assets|Company Balance Sheet Assets mustangbio.com (MBIO)|Company Total Assets TransCode Therapeutics, Inc. RNAZ|Aggregate Company Assets Bionano Genomics Inc. BNGO|Company Total Assets APDN (Applied DNA Sciences)|BLUE: Company Total Asset Base|Aggregate Company Assets IPA|Omega Therapeutics Inc (OMGA) - Company Assets|Company Total Assets Singular Genomics Systems Inc (OMIC)|Total Business Assets RGLS|Aggregate Company Assets Syros Pharmaceuticals SYRS|Total Business Assets telesisbio.com (TBIO)|Company Total Assets TCON (TRACON Pharmaceuticals, Inc.)|Company Total Assets Unity Biotechnology Inc. UBX